In June 2020, George (WG99) and John (WG02) cofounded D3 Bio, Inc with substantial funding from a group of global syndicated investors. Ran (W/C’14) joined D3 Bio right after she led the Series A investment in the company for Matrix Partners China.D3 Bio, Inc is an “in China, for global” biotech company aiming to become a world-class biotherapeutic company to develop and register the best-in-class medicines for cancer and autoimmune disease patients in large unmet medical needs through a continuously progressing cycle of Development to Discovery and back to Development process. The company has launched 5 pre-clinical portfolio projects with first and best in class potential. Prior to founding D3 Bio, Inc, George was a SVP of Global R&D Oncology and Head of R&D China at AstraZeneca, where, under his leadership, his team successfully created a robust portfolio with 90 development projects and achieved 35 China NDA/sNDA/BLA approvals, including Tagrisso, Lymparza, Linzess, Imfinizi, Forxiga, Breztri, Bevespi, Lokelma, etc. John came from 20+ years of drug development, management and business development experience at Millinium, Eli Lilly, BeiGene, etc. He was most recently the Founding Managing Partner of Hanne Capital. Ran, a graduate from the Roy Vagelos Life Science Management Program, was most recently a biotech venture capitalist at Matrix Partners China, a top-performing fund under Penn’s endowment portfolio.
Contact John at:
Contact Ran at: